500 patients67,039 observations150 daysLIVE

Patient P-03114

Synthetic patientONX-7 · Day 150 · 25–34 · M · baseline S11Open companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
6%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S11
  2. Day 13 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 18 DT-01 recommendedDosing / Timing Recommendation DT-01
  4. Day 19 Patient acceptedStarted DT-01 in the companion
  5. Day 24 GI symptom burden −24% vs expectedDosing / Timing Recommendation DT-01
  6. Day 30 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 13.

Primary contributors, last 14 days
  • GI instability-12
  • Nutritional resilience+10
  • Toxicity-9
  • Inflammatory activity-6

What helped?

  • Dosing / Timing Recommendation DT-01Day 18
    Result: symptom burden −24%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients.

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Drug metabolism and exposure 75
    • DNACYP2D6 poor metabolizer → higher exposure
    • DNADPYD *2A → slower clearance
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 37/100
    • MicrobiomeF. prausnitzii depleted
  • Mucosal barrier integrity 30
    • MicrobiomeAkkermansia low → thinner mucus layer
  • Inflammatory signalling 20
    • MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
  • MTHFR C677T
    Reduced folate turnover
Microbiome
Shannon diversity 2.4 · butyrate capacity 37/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
69 ms
Sleep
7.0 h
Steps
4,504
Resting HR
72 bpm
Daily log: GI score 13, nutritional resilience 73, adherence 93.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Keep meals regular; three to four moderate portions spaced through the day
  • Include a cooked vegetable portion with each main meal
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Log the daily check-in; one line is enough
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • No additional supplements this week
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0306256%S1144
P-0314354%S11DT-01improved49
P-0344253%S11DT-01improved51
P-0340851%S09HY-01improved53
P-0326847%S15DT-01improved56
P-0333947%S1949
P-0316746%S1853
P-0319346%S13DT-01improved53
P-0347545%S20HY-01improved50
P-0306744%S06DT-01no change50
P-0339244%S15GI-04improved52
P-0324442%S08DT-01improved53